Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma

Published:2019-10-16 Issue: Volume:10 Page:
ISSN:1664-8021
Container-title:Frontiers in Genetics
language:
Short-container-title:Front. Genet.

Author:

Ribeiro Marcelo L.,Reyes-Garau Diana,Armengol Marc,Fernández-Serrano Miranda,Roué Gaël

Funder

Instituto de Salud Carlos III

TG Therapeutics

Celgene

Publisher

Frontiers Media SA

Subject

Genetics (clinical),Genetics,Molecular Medicine

Reference284 articles.

1. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value;Abbas;Blood,2010

2. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2;Abd Al Kader;Virchows Arch.,2013

3. Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma;Agarwal;Nat. Med.,2019

4. The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death;Ageberg;Am. J. Transl. Res.,2013

5. Nucleosidic DNA demethylating epigenetic drugs —A comprehensive review from discovery to clinic;Agrawal;Pharmacol. Ther.,2018

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Regulation of Autophagy in Bone Metabolism;Function;2024

2. Synthesis and application of small molecules approved for the treatment of lymphoma;European Journal of Medicinal Chemistry;2023-12

3. Editorial: Diagnosis and therapy pediatric hematological malignancies: recent progress;Frontiers in Pediatrics;2023-10-26

4. Phytochemicals in cervical cancer: an epigenetic overview;Epigenomics;2023-09

5. Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents;Journal of Hematology & Oncology;2023-08-25